Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LKM002
MIFTS: 67

Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia

About this section

MalaCards integrated aliases for Leukemia:

Name: Leukemia 12 74 29 54 42 44 15 37 17 71
Leukemias 15

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1240
ICD9CM 34 208
MeSH 44 D007938
NCIt 50 C3161
SNOMED-CT 67 255049003
UMLS 71 C0023418
Sources

Summaries for Leukemia

About this section
MedlinePlus : 42 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. There are different types of leukemia, including Acute lymphocytic leukemia Acute myeloid leukemia Chronic lymphocytic leukemia Chronic myeloid leukemia Leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; children with leukemia most often have an acute type. Some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. NIH: National Cancer Institute

MalaCards based summary : Leukemia, also known as leukemias, is related to myeloid leukemia and acute leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia is MIR27A (MicroRNA 27a), and among its related pathways/superpathways are Endometrial cancer and MicroRNAs in cancer. The drugs Azacitidine and Decitabine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 74 Leukemia, also spelled leukaemia, is a group of blood cancers that usually begin in the bone marrow and... more...

Sources

Related Diseases for Leukemia

About this section

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2791)
# Related Disease Score Top Affiliating Genes
1 myeloid leukemia 33.9 RUNX1 RAF1 NPM1 LIF KIT FLT3
2 acute leukemia 33.7 RUNX1 PBX1 NPM1 KIT FLT3 ETV6
3 leukemia, chronic myeloid 33.6 RUNX1 RAF1 PML KIT HOTAIR FLT3
4 childhood leukemia 33.5 RUNX1 PBX1 ETV6 BCR ABL1
5 childhood acute lymphocytic leukemia 33.5 RUNX1 PBX1 FLT3 ETV6 BCR ABL1
6 t-cell acute lymphoblastic leukemia 33.4 RUNX1 FLT3 ETV6 ABL1
7 chronic myelomonocytic leukemia 33.4 RUNX1 NPM1 KIT FLT3 ETV6
8 juvenile myelomonocytic leukemia 33.3 RUNX1 RAF1 FLT3 ETV6
9 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.3 RUNX1 KIT FLT3 ETV6
10 b-lymphoblastic leukemia/lymphoma 33.3 PBX1 KIT FLT3 ETV6 BCR ABL1
11 leukemia, acute lymphoblastic 33.3 TCL1A RUNX1 PBX1 MIR27A KIT FLT3
12 acute myeloblastic leukemia with maturation 33.2 NPM1 KIT FLT3
13 atypical chronic myeloid leukemia 33.2 RUNX1 FLT3 ETV6 ABL1
14 core binding factor acute myeloid leukemia 33.2 RUNX1 KIT FLT3
15 precursor t-cell acute lymphoblastic leukemia 33.1 TCL1A FLT3 ETV6 BCR ABL1
16 acute megakaryocytic leukemia 33.1 RUNX1 KIT FLT3
17 chronic eosinophilic leukemia 33.1 KIT FLT3 ETV6 ABL1
18 myelodysplastic syndrome 33.1 RUNX1 NPM1 KIT FLT3 ETV6 ABL1
19 adult acute lymphocytic leukemia 33.0 PBX1 ETV6 ABL1
20 chronic leukemia 33.0 KIT FLT3 BCR ABL1
21 leukemia, acute lymphoblastic 3 33.0 RUNX1 PBX1 FLT3 ETV6 BCR ABL1
22 leukemia, chronic lymphocytic 33.0 TCL1A NEAT1 MIR27A FLT3 BCR ABL1
23 acute myeloblastic leukemia without maturation 33.0 NPM1 FLT3
24 cytogenetically normal acute myeloid leukemia 32.9 NPM1 FLT3
25 b-cell adult acute lymphocytic leukemia 32.9 PBX1 BCR ABL1
26 childhood acute myeloid leukemia 32.9 NPM1 KIT FLT3
27 myeloproliferative neoplasm 32.9 RUNX1 KIT FLT3 ETV6 BCR ABL1
28 b-lymphoblastic leukemia/lymphoma with hypodiploidy 32.8 PBX1 ETV6 ABL1
29 myelodysplastic/myeloproliferative neoplasm 32.8 KIT FLT3 ETV6 ABL1
30 acute promyelocytic leukemia 32.7 RUNX1 PML NPM1 NEAT1 HOTAIRM1 FLT3
31 b-lymphoblastic leukemia/lymphoma with iamp21 32.6 PBX1 ETV6 ABL1
32 cebpa-associated familial acute myeloid leukemia 32.6 RUNX1 NPM1 KIT FLT3 ETV6
33 etv6 thrombocytopenia and predisposition to leukemia 32.5 RUNX1 NPM1 KIT FLT3 ETV6
34 8p11 myeloproliferative syndrome 32.5 RUNX1 KIT FLT3 BCR
35 myeloid sarcoma 32.5 NPM1 KIT FLT3
36 testicular leukemia 32.3 ETV6 ABL1
37 philadelphia-negative chronic myeloid leukemia 32.2 BCR ABL1
38 acute myeloid leukemia with t(8;21)(q22;q22) translocation 32.2 RUNX1 KIT FLT3
39 leukemia, acute myeloid 32.0 RUNX1 PML PBX1 NPM1 MIR331 MIR27A
40 myelofibrosis 31.7 RUNX1 NPM1 KIT FLT3 ETV6 CDKN2B-AS1
41 lymphoma, non-hodgkin, familial 31.5 TCL1A NPM1 MIR331 MIR27A FLT3 ETV6
42 b-cell lymphoma 31.3 TCL1A NPM1 HOTAIR GAS5 BCR
43 blood platelet disease 31.3 RUNX1 KIT FLT3 ABL1
44 hematologic cancer 31.2 RUNX1 NPM1 MIR331 MIR27A KIT FLT3
45 myeloma, multiple 31.1 MIR331 MIR27A KIT HOTAIR GAS5 FLT3
46 gastrointestinal stromal tumor 30.8 RAF1 KIT HOTAIR FLT3 ABL1
47 aggressive systemic mastocytosis 30.8 RUNX1 KIT FLT3
48 bone marrow cancer 30.5 NPM1 MIR27A KIT FLT3 ABL1
49 pediatric lymphoma 30.5 TCL1A NPM1
50 renal cell carcinoma, nonpapillary 30.0 RAF1 MIR27A KIT HOTAIR GAS5 FLT3

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia
Sources

Symptoms & Phenotypes for Leukemia

About this section

UMLS symptoms related to Leukemia:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FLT3 KIT
4 Increased HDAC inhibitor resistance GR00115-A-0 8.96 LIF LIFR
5 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.32 FLT3

MGI Mouse Phenotypes related to Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 ABL1 BCR ETV6 FLT3 KIT LIF
2 hematopoietic system MP:0005397 10.1 ABL1 BCR ETV6 FLT3 KIT LIF
3 endocrine/exocrine gland MP:0005379 10.07 ABL1 ETV6 FLT3 KIT LIF LIFR
4 embryo MP:0005380 10.06 ABL1 ETV6 KIT LIF LIFR NPM1
5 immune system MP:0005387 10.03 ABL1 BCR ETV6 FLT3 KIT LIF
6 liver/biliary system MP:0005370 9.85 ABL1 BCR ETV6 KIT LIF LIFR
7 neoplasm MP:0002006 9.5 ETV6 FLT3 KIT NPM1 PML RAF1
8 normal MP:0002873 9.23 ABL1 BCR ETV6 KIT PBX1 PML
Sources

Drugs & Therapeutics for Leukemia

About this section

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 778)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
2
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
7
ofatumumab Approved Phase 4 679818-59-8 6918251
8
Teniposide Approved Phase 4 29767-20-2 34698
9
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
10
Palonosetron Approved, Investigational Phase 4 135729-56-5, 119904-90-4 148211
11
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
12
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
13
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
14
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
15
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
16
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
17
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
18
Nitric Oxide Approved Phase 4 10102-43-9 145068
19
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
20
Busulfan Approved, Investigational Phase 4 55-98-1 2478
21
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
22
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
23
Prilocaine Approved Phase 4 721-50-6 4906
24
Chlorambucil Approved Phase 4 305-03-3 2708
25
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
26
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
27
Zidovudine Approved Phase 4 30516-87-1 35370
28
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
29
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
30
Uric acid Investigational Phase 4 69-93-2 1175
31
Ethylene Phase 4 74-85-1 6325
32 Serotonin 5-HT3 Receptor Antagonists Phase 4
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4
34 Cyclooxygenase Inhibitors Phase 4
35 Vitamin D2 Phase 4
36 Ergocalciferols Phase 4
37 Excitatory Amino Acid Antagonists Phase 4
38 Anesthetics, Inhalation Phase 4
39 Ketorolac Tromethamine Phase 4
40 Anesthetics, Dissociative Phase 4
41 Hydroxycholecalciferols Phase 4
42 Gemtuzumab Phase 4
43 Anti-Arrhythmia Agents Phase 4
44 Anesthetics, Local Phase 4
45 HH-GV-678 Phase 4
46 Diuretics, Potassium Sparing Phase 4
47 Aromatase Inhibitors Phase 4
48 Estrogen Receptor Antagonists Phase 4
49 Estrogen Antagonists Phase 4
50 Sodium Channel Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 6265)
# Name Status NCT ID Phase Drugs
1 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
2 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
3 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
4 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
5 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
6 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
7 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
9 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
10 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
11 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
12 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
13 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
14 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
15 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
16 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Unknown status NCT02926586 Phase 4 Fludarabine;Cytarabine
17 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
18 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Unknown status NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
19 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
20 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
21 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
22 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
23 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
24 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
25 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
26 Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
27 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
28 Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Unknown status NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG（Sanofi/Genzyme）
29 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
30 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
31 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
32 A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
33 AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
34 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
35 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
36 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
37 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
38 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
39 Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
40 German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
41 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
42 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
43 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
44 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
45 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib
46 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
47 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
48 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
49 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
50 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Isotretinoin
Methotrexate
Methotrexate Sodium
Pipobroman
Vincristine
Vincristine Sulfate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Leukemia:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244

Cochrane evidence based reviews: leukemia

Sources

Genetic Tests for Leukemia

About this section

Genetic tests related to Leukemia:

# Genetic test Affiliating Genes
1 Leukemia 29
Sources

Anatomical Context for Leukemia

About this section

MalaCards organs/tissues related to Leukemia:

40
Myeloid, T Cells, Bone Marrow, Bone, B Cells, Nk Cells, Breast
Sources

Publications for Leukemia

About this section

Articles related to Leukemia:

(show top 50) (show all 50094)
# Title Authors PMID Year
1
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. 42 61
33397387 2021
2
Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis. 42
33386934 2021
3
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. 42
33392702 2021
4
Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. 47
21070600 2011
5
Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins. 61 54
20362031 2010
6
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. 61 54
20435628 2010
7
Nup98-homeodomain fusions interact with endogenous Nup98 during interphase and localize to kinetochores and chromosome arms during mitosis. 54 61
20237156 2010
8
LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. 61 54
19701750 2010
9
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. 61 54
20223922 2010
10
Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. 54 61
20237505 2010
11
Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes. 61 54
19748670 2010
12
Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3. 61 54
20237320 2010
13
Genetic variation in the folate metabolic pathway and risk of childhood leukemia. 61 54
20101025 2010
14
MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. 54 61
20332322 2010
15
Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. 61 54
20236310 2010
16
c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin. 61 54
20124512 2010
17
Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia. 54 61
20062079 2010
18
Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways. 61 54
20231472 2010
19
MEIS proteins as partners of the TLX1/HOX11 oncoprotein. 54 61
19559479 2010
20
Analysis of Ikaros family splicing variants in human hematopoietic lineages. 61 54
20432734 2010
21
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). 54 61
20170098 2010
22
The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. 61 54
20038611 2010
23
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. 61 54
20072157 2010
24
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. 54 61
20008304 2010
25
The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. 61 54
20093438 2010
26
Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway. 54 61
20008789 2010
27
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. 54 61
20026798 2010
28
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. 54 61
20008787 2010
29
Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells. 61 54
19887369 2010
30
Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the anti-apoptotic protein bcl-2. 61 54
20237898 2010
31
Impact of breast cancer resistance protein on cancer treatment outcomes. 61 54
19949928 2010
32
Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines. 54 61
20084277 2010
33
Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. 54 61
19801969 2010
34
Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias. 61 54
19919827 2010
35
A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. 61 54
19880492 2010
36
[Expression of c-fes gene in leukemia cells and its clinical significance]. 54 61
20030920 2009
37
TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia. 54 61
19786618 2009
38
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. 61 54
19773546 2009
39
Effects of Manisa propolis on telomerase activity in leukemia cells obtained from the bone marrow of leukemia patients. 61 54
19817639 2009
40
Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis. 54 61
19907659 2009
41
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. 61 54
20032408 2009
42
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. 54 61
19734451 2009
43
High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. 61 54
19643984 2009
44
Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. 54 61
19666867 2009
45
New structural arrangement of the extracellular regions of the phosphate transporter SLC20A1, the receptor for gibbon ape leukemia virus. 61 54
19717569 2009
46
On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. 61 54
19556245 2009
47
Transformation from committed progenitor to leukemia stem cells. 61 54
19796242 2009
48
Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. 61 54
19682090 2009
49
HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. 61 54
19291801 2009
50
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. 61 54
19541823 2009
Sources

Variations for Leukemia

About this section

Copy number variations for Leukemia from CNVD:

7 (show all 44)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19383 1 150034000 245120000 Amplification Leukemia
2 33637 1 46800000 50700000 Loss Leukemia
3 44329 10 55250865 57057708 Rearrangement PCDH15 Leukemia
4 62297 12 10760000 26234000 Amplification Leukemia
5 64439 12 12800000 14800000 Gain SLC2A14 Leukemia
6 64440 12 12800000 14800000 Gain SLC2A3 Leukemia
7 69764 12 56263000 69037000 Amplification Leukemia
8 69765 12 56263000 69037000 Amplification Leukemia
9 74441 13 107000000 115169878 Loss Leukemia
10 77064 13 39703000 40042000 Amplification Leukemia
11 86548 14 62100000 64800000 Gain SYNE2 Leukemia
12 109053 17 24000000 81195210 Copy number SLC2A1 Leukemia
13 112810 17 41159000 78182000 Amplification Leukemia
14 127115 19 26500000 59128983 Gain Leukemia
15 134399 2 10062000 11645000 Amplification Leukemia
16 138038 2 15720000 16465000 Amplification Leukemia
17 138662 2 16873000 60356000 Amplification Leukemia
18 138663 2 16873000 60356000 Amplification Leukemia
19 147406 2 64333000 65547000 Amplification Leukemia
20 153044 20 33909000 62377000 Amplification Leukemia
21 156917 20 9002000 17491000 Amplification Leukemia
22 159831 21 45112000 46015000 Amplification Leukemia
23 161203 22 17722000 17723000 Amplification Leukemia
24 165015 22 41000000 44200000 Gain RRP7A Leukemia
25 165016 22 41000000 44200000 Gain SERHL Leukemia
26 172851 3 18696000 18818000 Amplification Leukemia
27 173075 3 189413414 190080135 Translate LPP Leukemia
28 191719 6 1 60500000 Loss of mismatch HLA-A Leukemia
29 191720 6 1 60500000 Loss of mismatch HLA-B Leukemia
30 191721 6 1 60500000 Loss of mismatch HLA-C Leukemia
31 200024 5 48400000 180915260 Deletion Leukemia
32 204999 6 118500000 171115067 Gain Leukemia
33 205139 6 121263000 130387000 Deletion Leukemia
34 206061 6 135502452 135540311 Gain MYB Leukemia
35 215006 6 70000000 114600000 Loss Leukemia
36 226598 7 59900000 159138663 Deletion Leukemia
37 246206 9 117700000 122500000 Loss Leukemia
38 250022 9 19900000 25600000 Deletion CDKN2A Leukemia
39 250028 9 19900000 25600000 Loss CDKN2A Leukemia
40 250692 9 21957750 21984490 Deletion CDKN2A Leukemia
41 253950 9 49000000 141213431 Deletion Leukemia
42 254016 9 50700000 114900000 Loss Leukemia
43 304060 5 23543480 23564463 Mutation PRDM9 Leukemia
44 304367 7 1780332 38257086 Deletion DOCK4 Leukemia
Sources

Expression for Leukemia

About this section
Search GEO for disease gene expression data for Leukemia.
Sources

Pathways for Leukemia

About this section

Pathways related to Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 36
Show member pathways
 12.45 RUNX1 RAF1 PML KIT FLT3 BCR
2
MicroRNAs in cancer 36
12.25 RAF1 MIR331 MIR27A ABL1
3
Pathways in cancer 36
12.22 RUNX1 RAF1 PML KIT FLT3 BCR
4
Transcriptional misregulation in cancer 36
11.94 RUNX1 PML PBX1 FLT3 ETV6
5
VEGF Pathway (Tocris) 60
Show member pathways
 11.5 RAF1 KIT FLT3
6
Central carbon metabolism in cancer 36
11.39 RAF1 KIT FLT3
7
Ponatinib Pathway, Pharmacokinetics/Pharmacodynamics 60
Show member pathways
 11.21 KIT BCR ABL1
8
Tyrosine Kinases / Adaptors 4
11.19 NPM1 KIT FLT3 BCR ABL1
9
G-protein signaling_Rap2B regulation pathway 23
10.73 RAF1 LIFR LIF KIT FLT3
Sources

GO Terms for Leukemia

About this section

Biological processes related to Leukemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.95 RAF1 KIT FLT3 BCR ABL1
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 RUNX1 RAF1 PBX1 NPM1 LIF ETV6
3 cytokine-mediated signaling pathway GO:0019221 9.84 LIFR LIF KIT FLT3
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.69 TCL1A RAF1 LIF
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 LIF KIT FLT3
6 hemopoiesis GO:0030097 9.63 RUNX1 KIT FLT3
7 somatic stem cell population maintenance GO:0035019 9.58 RAF1 PBX1 KIT
8 embryonic hemopoiesis GO:0035162 9.56 PBX1 KIT
9 protein autophosphorylation GO:0046777 9.56 KIT FLT3 BCR ABL1
10 hematopoietic stem cell proliferation GO:0071425 9.52 RUNX1 ETV6
11 leukemia inhibitory factor signaling pathway GO:0048861 9.48 LIFR LIF
12 regulation of cytokine-mediated signaling pathway GO:0001959 9.43 RUNX1 LIFR
13 regulation of cell differentiation GO:0045595 9.33 RUNX1 RAF1 LIF
14 myeloid progenitor cell differentiation GO:0002318 9.32 KIT FLT3
15 positive regulation of cell proliferation GO:0008284 9.17 TCL1A PBX1 NPM1 LIFR LIF KIT
16 thymus development GO:0048538 9.13 RAF1 PBX1 ABL1
Sources

Sources for Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....